title: Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.
abstract: BACKGROUND
  Severe bleeding associated with dabigatran frequently requires intensive care management. An antidote is currently unavailable and data reporting the effect of dialysis on elimination of dabigatran are encouraging, but limited. Objective. To report the effect of intermittent hemodialysis (IHD) and continuous renal replacement therapy (CRRT) at enhancing elimination of dabigatran.
  
  
  METHODS
  Patients were identified by existing collaborative networks. Pre-filter dabigatran plasma concentrations were measured in all patients, and in dialysate of three patients.
  
  
  RESULTS
  Seven patients received dialysis, five with active bleeding and two requiring emergent surgery. Five received IHD and two received CRRT. The plasma elimination half-life of dabigatran was 1.5-4.9 h during IHD, and 14.0-27.5 h during CRRT. Mean dabigatran plasma clearance during IHD was 85-169 mL/min in three patients. Time to obtain a subtherapeutic dabigatran concentration depended on the initial concentration, being 8-18 h for IHD in three patients while 4 h was insufficient in a supratherapeutic case. A 38% rebound in dabigatran levels occurred after one case during IHD, and thrombin time increased after IHD in another, but not after 144 h CRRT or 17 h IHD in two others; data were incomplete in three cases. The amount removed during IHD was proportional to the pre-IHD concentration and clearance, but was consistently low at 3.3-17.4 mg in three patients where this was determined. Moderate bleeding occurred while obtaining vascular access in one patient. Two patients died from intracerebral bleeding, and the influence of treatments could not be determined in these cases.
  
  
  CONCLUSIONS
  IHD enhanced elimination of dabigatran more efficiently than CRRT, but their net effect remains poorly defined. Dialysis decisions, including modality and duration, must be individualized based on a risk-benefit assessment.
authors: Department of Nephrology, Hôpital du Sacré-Coeur de Montréal, University of Montreal , Montreal , Canada.
authors: Josée
authors: J
authors: Bouchard
authors: Marc
authors: M
authors: Ghannoum
authors: Amélie
authors: A
authors: Bernier-Jean
authors: David
authors: D
authors: Williamson
authors: Geoffrey
authors: G
authors: Kershaw
authors: Claire
authors: C
authors: Weatherburn
authors: Josette M
authors: JM
authors: Eris
authors: Huyen
authors: H
authors: Tran
authors: Jignesh P
authors: JP
authors: Patel
authors: Darren M
authors: DM
authors: Roberts
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000991:Antithrombins / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics; D001562:Benzimidazoles / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D002543:Cerebral Hemorrhage / Q000097:blood / Q000139:chemically induced / Q000628:therapy; D000069604:Dabigatran; D016903:Drug Monitoring; D017809:Fatal Outcome; D005260:Female; D006207:Half-Life; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced / Q000628:therapy*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D006435:Renal Dialysis / Q000379:methods*; D017582:Renal Replacement Therapy / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D000069604:Dabigatran
keywords: Bleeding; Dabigatran; Dialysis; Elimination; Extracorporeal; Toxicity